Abstract: A process for preparing a modified heat-treated platelet pellet lysate, said process comprising the steps of: a) Providing a platelet pellet lysate, b) Heat-treating the platelet pellet lysate at a temperature of 55° C. to 65° C. during 20 to 40 minutes, c) Purifying the heat-treated platelet pellet lysate of step b) so as to obtain a modified heat treated platelet pellet lysate having a total protein content of less than 70% of the total protein content of the platelet pellet lysate of step a).

Abstract: Process for preparing a heat-treated pooled human platelet lysate, said process comprising the steps of: a) Providing a pooled human platelet lysate (p HPL), b) Heat-treating the pooled human platelet lysate at a temperature of 50° C. to 70° C. during 20 to 40 minutes, c) Purifying the heat-treated pooled human platelet lysate of step b).

Abstract: A system and method for analyzing volatile organic compounds (VOCs) adsorbed on an adsorbent membrane, by low-temperature plasma and mass spectrometry (LTP-MS). The system includes a receptacle for receiving the adsorbent membrane, a low-temperature plasma ionizer configured to emit a plasma stream in a plasma emission direction, thereby ionizing the VOCs adsorbed by the membrane and forming a VOC-laden ionized gas, and a mass spectrometer for analyzing the ionized VOCs.

Abstract: System (1) for treatment by photodynamic therapy comprising an illuminating member (6) which comprises: —a core (35) carrying a light emitting surface (37), and —a hollow sheath (10) adapted to receive the core (35) with the light emitting surface (37) arranged within a balloon (11), the balloon (11) comprising a wall (12) which has an inner surface delimiting an internal space, and an outer surface, the wall (12) being flexible, wherein the internal space of the balloon (11) has a variable capacity, the wall (12) of the balloon (11) being elastically extendible and the balloon (11) presenting a plurality of inflated states in each of which the internal space is filled with a volume of light diffusing solution, and wherein the system further comprises a support provided with a transfer function relating the volume of light diffusing solution of each inflated state with at least one of a corresponding distribution of light power at the outer surface of the wall (12) of the balloon (11) and a corresponding time

Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

Abstract: The system comprises: —a bundle of light fibers (11) connected to a light-emitting source (8), and both transmitting light inside the light fiber and emitting light toward a treatment volume (V), —a temperature-modifying system attached to the bundle of light fibers (11) to modify temperature in the treatment volume (V).

Abstract: An optical fiber mode scrambler adapted to give a determined bending to an optical fiber inserted in the mode scrambler, the mode scrambler having a general extension direction X, the mode scrambler having a morphology adapted to give the optical fiber a direction along X at the entry of the scrambler, and then to bend the fiber to bring the fiber substantially in the X, Y plan in the ?X and Y directions, before bringing the fiber in a rotation around the X axis substantially in the Y, Z plan in the anti clockwise direction for one full rotation, and then bending the fiber to bring the fiber substantially in the X, Y plan in the ?X and ?Y directions, and then bending the fiber to give the optical fiber a direction along X at the exit of the scrambler.

Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

Abstract: The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its administration.

Abstract: The present invention relates to the compound having Formula (I) or pharmaceutically acceptable salts or solvates thereof, and its use in treating and/or preventing a Tauopathy.